Breast cancer (Tokyo, Japan)最新文献

{"title":"Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.","authors":"Venhar Cınar,&nbsp;Zuhal Hamurcu,&nbsp;Ahsen Guler,&nbsp;Nursultan Nurdinov,&nbsp;Bulent Ozpolat","doi":"10.1007/s12282-022-01391-9","DOIUrl":"https://doi.org/10.1007/s12282-022-01391-9","url":null,"abstract":"<p><strong>Background: </strong>Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer and associated with poor prognosis and shorter survival due to significant genetic heterogeneity, drug resistance and lack of effective targeted therapeutics. Therefore, novel molecular targets and therapeutic strategies are needed to improve patient survival. Serotonin (5-hydroxytryptamine, 5-HT) has been shown to induce growth stimulatory effects in breast cancer. However, the molecular mechanisms by which 5-HT exerts its oncogenic effects in TNBC still are not well understood.</p><p><strong>Methods: </strong>Normal breast epithelium (MCF10A) and two TNBC cells (MDA-MB-231, BT-546) and MCF-7 cells (ER +) were used to investigate effects of 5-HT7 receptor. Small interfering RNA (siRNA)-based knockdown and metergoline (5-HT7 antagonist) were used to inhibit the activity of 5-HT7. Cell proliferation and colony formation were evaluated using MTS cell viability and colony formation assays, respectively. Western blotting was used to investigate 5-HT7, FOXM1 and its downstream targets protein expressions.</p><p><strong>Results: </strong>We demonstrated that 5-HT induces cell proliferation of TNBC cells and expression of 5-HT7 receptor and FOXM1 oncogenic transcription factor. We found that expression of 5-HT7 receptor is up-regulated in TNBC cells and higher 5-HT7 receptor expression is associated with poor patient prognosis and shorter patient survival. Genetic and pharmacological inhibition of 5-HT7 receptor by siRNA and metergoline, respectively, suppressed TNBC cell proliferation and FOXM1 and its downstream mediators, including eEF2-Kinase (eEF2K) and cyclin-D1.</p><p><strong>Conclusion: </strong>Our findings suggest for the first time that the 5-HT7 receptor promotes FOXM1, eEF2K and cyclin D1 signaling to support TNBC cell proliferation; thus, inhibition of 5-HT7 receptor/FOXM1 signaling may be used as a potential therapeutic strategy for targeting TNBC. 5-HT induces cell proliferation of TNBC cells through 5-HT7 receptor signaling. Also, genetic and pharmacological inhibition of 5-HT7 by RNAi (siRNA) and metergoline HTR7 antagonist, respectively inhibits FOXM1 oncogenic transcription factor and suppresses TNBC cell proliferation.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1106-1120"},"PeriodicalIF":4.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40427074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between mammographic breast composition and breast cancer risk among Japanese women: a retrospective cohort study.","authors":"Toshifumi Namba,&nbsp;Naoko Matsuda,&nbsp;Mahbubur Rahman,&nbsp;Naoki Kanomata,&nbsp;Hideko Yamauchi,&nbsp;Hiroko Tsunoda","doi":"10.1007/s12282-022-01376-8","DOIUrl":"https://doi.org/10.1007/s12282-022-01376-8","url":null,"abstract":"<p><strong>Background: </strong>Mammographic breast composition is associated with breast cancer risk. However, evidence in a Japanese cohort investigating this association is scarce. Thus, we aimed to compare breast cancer risk between women with and without dense breasts.</p><p><strong>Methods: </strong>All Japanese women who underwent breast cancer screening at a tertiary care academic hospital-affiliated preventive center at least twice with known baseline mammographic breast composition were included in this study. A single-center retrospective cohort study was conducted among 24,863 women who had 125,566 screening opportunities between April 1, 2005, and March 31, 2015. All women were categorized into two groups based on their baseline breast composition: women with dense breasts (13,815) and women with non-dense breasts (11,048). We compared the demographic characteristics between the two groups. After calculating person-years, Cox proportional hazards analyses were performed to estimate the hazard ratio (HR) of developing breast cancer according to breast composition status.</p><p><strong>Results: </strong>During the study period, 358 breast cancer cases were identified. The dense and non-dense groups differed significantly by age, body mass index, family history of breast cancer, physical activity, history of smoking and alcohol consumption, number of pregnancies, and number of deliveries. After adjusting for these factors, Cox proportional hazards analyses showed that women with dense breasts had a significantly higher HR for developing breast cancer than women without dense breasts. The association was even stronger in younger women (≤ 50 years old), but it did not achieve statistical significance in older women.</p><p><strong>Conclusion: </strong>Dense breasts at baseline are a risk factor for developing breast cancer in Japanese women. However, this association was only observed in women aged 50 years or younger at the time of entry into the screening program.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"978-984"},"PeriodicalIF":4.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40501235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: BAHD1 serves as a critical regulator of breast cancer cell proliferation and invasion.","authors":"Ze-Yu Yang,&nbsp;Su-Peng Yin,&nbsp;Qingnan Ren,&nbsp;Deng-Wei Lu,&nbsp;Tao Tang,&nbsp;Yao Li,&nbsp;Yi-Zeng Sun,&nbsp;Hong-Biao Mo,&nbsp;Ting-Jie Yin,&nbsp;Zi-Ying Yi,&nbsp;Jun-Ping Zhu,&nbsp;Fan Zhang,&nbsp;Hongdan Chen","doi":"10.1007/s12282-022-01402-9","DOIUrl":"https://doi.org/10.1007/s12282-022-01402-9","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1140"},"PeriodicalIF":4.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40362660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Internal mammary lymph node metastasis in breast cancer patients based on anatomical imaging and functional imaging.","authors":"Wei Wang,&nbsp;Pengfei Qiu,&nbsp;Jianbin Li","doi":"10.1007/s12282-022-01377-7","DOIUrl":"https://doi.org/10.1007/s12282-022-01377-7","url":null,"abstract":"<p><p>Internal mammary lymph node (IMLN) metastasis forms part of the clinical node classification for primary breast cancer, which influences the treatment strategy. However, because of the IMLNs' complicated anatomical structures and relationships with adjacent structures, IMLN biopsy or resection is associated with a limited improvement in prognosis and a high complication rate. The positivity rate also varies broadly according to imaging modality, and there is a low rate of agreement between the imaging and pathological diagnoses, which creates imprecision in the preoperative staging. The IMLN positivity rate also varies remarkably, and there are no clear, accurate, and non-invasive modalities for diagnosing the pre-mastectomy IMLN status. Nevertheless, medical imaging modalities continue to evolve, with functional imaging and image-guided thoracoscopic biopsy of sentinel IMLNs being well established. Thus, personalized decision-making and treatment selection should be based on the modality-specific differences in the diagnosis of IMLN metastasis/recurrence and the patient's specific risk factors.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"933-944"},"PeriodicalIF":4.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40398135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan.","authors":"Akihiko Shimomura,&nbsp;Masayuki Nagahashi,&nbsp;Hiraku Kumamaru,&nbsp;Kenjiro Aogi,&nbsp;Sota Asaga,&nbsp;Naoki Hayashi,&nbsp;Kotaro Iijima,&nbsp;Takayuki Kadoya,&nbsp;Yasuyuki Kojima,&nbsp;Makoto Kubo,&nbsp;Minoru Miyashita,&nbsp;Hiroaki Miyata,&nbsp;Naoki Niikura,&nbsp;Etsuyo Ogo,&nbsp;Kenji Tamura,&nbsp;Kenta Tanakura,&nbsp;Masayuki Yoshida,&nbsp;Yutaka Yamamoto,&nbsp;Shigeru Imoto,&nbsp;Hiromitsu Jinno","doi":"10.1007/s12282-022-01378-6","DOIUrl":"https://doi.org/10.1007/s12282-022-01378-6","url":null,"abstract":"<p><strong>Background: </strong>Male breast cancer (MBC) is rare; however, its incidence is increasing. There have been no large-scale reports on the clinicopathological characteristics of MBC in Japan.</p><p><strong>Methods: </strong>We investigated patients diagnosed with breast cancer in the Japanese National Clinical Database (NCD) between January 2012 and December 2018.</p><p><strong>Results: </strong>A total of 594,316 cases of breast cancer, including 3780 MBC (0.6%) and 590,536 female breast cancer (FBC) (99.4%), were evaluated. The median age at MBC and FBC diagnosis was 71 (45-86, 5-95%) and 60 years (39-83) (p < 0.001), respectively. MBC cases had a higher clinical stage than FBC cases: 7.4 vs. 13.3% stage 0, 37.2 vs. 44.3% stage I, 25.6 vs. 23.9% stage IIA, 8.8 vs. 8.4% stage IIB, 1.9 vs. 2.4% stage IIIA, 10.1 vs. 3.3% stage IIIB, and 1.1 vs. 1.3% stage IIIC (p < 0.001). Breast-conserving surgery was more frequent in FBC (14.6 vs. 46.7%, p = 0.02). Axillary lymph node dissection was more frequent in MBC cases (32.9 vs. 25.2%, p < 0.001). Estrogen receptor(ER)-positive disease was observed in 95.6% of MBC and 85.3% of FBC cases (p < 0.001). The HER2-positive disease rates were 9.5% and 15.7%, respectively (p < 0.001). Comorbidities were more frequent in MBC (57.3 vs. 32.8%) (p < 0.001). Chemotherapy was less common in MBC, while endocrine therapy use was similar in ER-positive MBC and FBC. Perioperative radiation therapy was performed in 14.3% and 44.3% of cases.</p><p><strong>Conclusion: </strong>Japanese MBC had an older age of onset, were more likely to be hormone receptor-positive disease, and received less perioperative chemotherapy than FBC.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"985-992"},"PeriodicalIF":4.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40210150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of dedicated breast positron emission tomography.","authors":"Rikako Hashimoto,&nbsp;Sadako Akashi-Tanaka,&nbsp;Chie Watanabe,&nbsp;Hiroko Masuda,&nbsp;Kanae Taruno,&nbsp;Tomoko Takamaru,&nbsp;Yoshimi Ide,&nbsp;Takashi Kuwayama,&nbsp;Yasuhiro Kobayashi,&nbsp;Masafumi Takimoto,&nbsp;Seigo Nakamura","doi":"10.1007/s12282-022-01381-x","DOIUrl":"https://doi.org/10.1007/s12282-022-01381-x","url":null,"abstract":"<p><strong>Background: </strong>Dedicated breast positron emission tomography (dbPET) has been developed for detecting smaller breast cancer. We investigated the diagnostic performance of dbPET in patients with known breast cancer.</p><p><strong>Methods: </strong>Eighty-two preoperative patients with breast cancer were included in the study (84 tumours: 11 ductal carcinomas in situ [DCIS], 73 invasive cancers). They underwent mammography (MMG), ultrasonography (US), and contrast-enhanced breast magnetic resonance imaging (MRI) before whole-body PET/MRI (WBPET/MRI) and dbPET. We evaluated the sensitivity of all modalities, and the association between the maximum standard uptake value (SUVmax) level and histopathological features.</p><p><strong>Results: </strong>The sensitivities of MMG, US, MRI, WBPET/MRI and dbPET for all tumours were 81.2% (65/80), 98.8% (83/84), 98.6% (73/74), 86.9% (73/84), and 89.2% (75/84), respectively. For 11 DCIS and 22 small invasive cancers (≤ 2 cm), the sensitivity of dbPET (84.9%) tended to be higher than that of WBPET/MRI (69.7%) (p = 0.095). Seven tumours were detected by dbPET only, but not by WBPET/MRI. Five tumours were detected by only WBPET/MRI because of the blind area of dbPET detector, requiring a wider field of view. After making the mat of dbPET detector thinner, all 22 scanned tumours were depicted. The higher SUVmax of dbPET was significantly related to the negative oestrogen receptor status, higher nuclear grade, and higher Ki67 (p < 0.001).</p><p><strong>Conclusions: </strong>The sensitivity of dbPET for early breast cancer was higher than that of WBPET/MRI. High SUVmax was related to aggressive features of tumours. Moreover, dbPET can be used for the diagnosis and oncological evaluation of breast cancer.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1013-1021"},"PeriodicalIF":4.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40405174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of community-based exercise on fatigue in early breast cancer survivors: identifying potential determinants of change.","authors":"Chad W Wagoner,&nbsp;Jordan T Lee,&nbsp;Erik D Hanson,&nbsp;Zachary Y Kerr,&nbsp;Kirsten A Nyrop,&nbsp;Hyman B Muss,&nbsp;Claudio L Battaglini","doi":"10.1007/s12282-022-01380-y","DOIUrl":"https://doi.org/10.1007/s12282-022-01380-y","url":null,"abstract":"<p><strong>Background: </strong>Exercise has been shown to reduce fatigue in early breast cancer survivors (EBCS), though it is unclear if these results translate to community-based exercise settings. Mechanisms that influence changes in fatigue seen after exercise are also poorly understood. This study sought to evaluate the impact of community-based exercise and identify associations of fatigue in EBCS.</p><p><strong>Methods: </strong>Twenty-nine EBCS and 13 non-cancer controls (CON) enrolled. Pre/post-intervention measurements included measures of fitness/function, balance, and adherence/compliance as well as self-reported measures of fatigue, health-related quality of life (HRQOL), well-being, self-efficacy, and physical activity. Both groups participated in a supervised 16-week aerobic + resistance exercise intervention. A mixed model ANOVA and Cohen's D effect size assessed fatigue changes, and univariable linear regressions identified fatigue associations.</p><p><strong>Results: </strong>Fatigue improved for EBCS (- 2.6, Cohen's D = 0.51) but not CON (0.0, Cohen's D = 0.02); no interaction effect was observed. Post-intervention fatigue in EBCS was associated with better QOL (R² = 0.387; p < 0.01), depression (R² = 0.251; p < 0.01), self-efficacy, (R² = 0.453; p < 0.01), outcome expectations from exercise (R² = 0.254; p < 0.01), balance (R² = 0.167; p < 0.05), and the 6-minute walk test (R² = 0.193; p < 0.05). EBCS improvements in fatigue were associated with improvements in self-reported physical health (R² = 0.425; p < 0.01), depression (R² = 0.233; p < 0.01), pain (R² = 0.157; p < 0.05), outcome expectations from exercise (R² = 0.420; p < 0.01), and the 6-minute walk test (R² = 0.172; p < 0.05). Less fatigue in the CON group was shown be associated with better sleep quality (R² = 0.309; p < 0.05) and pain (R² = 0.259; p < 0.05).</p><p><strong>Conclusion: </strong>Community-based exercise appears beneficial for alleviating fatigue in EBCS. These improvements may be driven by parallel improvements in psychosocial outcomes and objectively measured functional outcomes.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1001-1012"},"PeriodicalIF":4.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40396070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of breast cosmetic changes with a computer-software; the breast cancer conservative treatment cosmetic results (BCCT. core) in hypofractionated whole breast irradiation after breast-conserving surgery-supplementary analysis of multicenter single-arm confirmatory trial: JCOG0906.","authors":"Miwako Nozaki,&nbsp;Yoshikazu Kagami,&nbsp;Mitsuhiro Takahashi,&nbsp;Ryunosuke Machida,&nbsp;Yuta Sekino,&nbsp;Taro Shibata,&nbsp;Yoshinori Ito,&nbsp;Yasumasa Nishimura,&nbsp;Teruki Teshima,&nbsp;Hiroki Ushijima,&nbsp;Yasushi Nagata,&nbsp;Yasuo Matsumoto,&nbsp;Tetsuo Akimoto,&nbsp;Kana Takahashi,&nbsp;Shigeyuki Murayama,&nbsp;Takashi Uno,&nbsp;Kayoko Tsujino,&nbsp;Yasushi Hamamoto,&nbsp;Keiichi Nakagawa,&nbsp;Takeshi Kodaira,&nbsp;Masahiro Hiraoka","doi":"10.1007/s12282-022-01384-8","DOIUrl":"https://doi.org/10.1007/s12282-022-01384-8","url":null,"abstract":"<p><strong>Background: </strong>A good cosmetic outcome has been defined as an important endpoint in breast-conserving therapy (BCT). Various evaluation methods have been studied, but the optimal method has yet to be identified. The present supplementary analysis of JCOG0906 focused on comparing evaluation methods for breast cosmetic outcomes following hypofractionated whole breast irradiation (HFWBI) to examine whether a computer-software (the Breast Cancer Conservative Treatment cosmetic results [BCCT. core])-based program evaluation (CE) can be used for Asian women in clinical trials of BCT.</p><p><strong>Methods: </strong>Of 306 women, 292 underwent institutional evaluation (IE) for breast cosmetic outcomes before (pre) and 3 years after (post) HFWBI using a 4-point scale (excellent/good/fair/poor), and they were evaluated by CE and a central panel evaluation (PE) on the same scale using 292 pairs of pre/post-HFWBI photographs. PE was performed twice by consensus of the same two experts with a 3-year interval. CE was assessed individually by two radiation oncologists, an expert and a non-expert. Intra-observer variability and inter-observer variability were calculated using the kappa (k) and weighted kappa (wk) statistics.</p><p><strong>Results: </strong>The agreement between the first and second PE using pre/post-HFWBI photographs was moderate (k = 0.60, wk = 0.64. k = 0.53, wk = 0.60). The agreement between the expert and non-expert on CE was substantial (k = 0.72, wk = 0.76. k = 0.72, wk = 0.77). The inter-observer variability of CE was smaller than the intra-observer variability of PE.</p><p><strong>Conclusion: </strong>CE with BCCT. core was considered a reproducible and an appropriate evaluation method for Asian women in clinical trials of BCT, when breast cosmetic changes were compared between pre/post therapy.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1042-1049"},"PeriodicalIF":4.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40542090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive analysis of DRAIC and TP53TG1 in breast cancer luminal subtypes through the construction of lncRNAs regulatory model.","authors":"Jamshid Motalebzadeh,&nbsp;Elaheh Eskandari","doi":"10.1007/s12282-022-01385-7","DOIUrl":"https://doi.org/10.1007/s12282-022-01385-7","url":null,"abstract":"<p><strong>Background: </strong>Deciphering new molecules related to the breast cancer subtypes is crucial for prognosis and determining a better strategy for targeted therapy. In this study, we aimed to model ceRNAs networks in luminal A and luminal B subtypes of breast cancer and then delve deeper into the role of two candidate lncRNAs in breast tumors.</p><p><strong>Methods: </strong>We constructed two networks as a regulatory model based on our previously identified transcription factors (TFs) and miRNAs with associated lncRNAs. Then, we highlighted the role of some lncRNAs in luminal subtypes of breast cancer using available online databases. Furthermore, we empirically quantified the expression levels of two candidate lncRNAs (DRAIC and TP53TG1) in breast tumors and normal tissues.</p><p><strong>Results: </strong>Here, we proposed a regulatory model for TFs-miRNAs-lncRNAs in luminal subtypes of breast cancer. We found 18 and 17 differentially expressed lncRNAs in luminal A and luminal B subtypes, respectively. Of these lncRNAs, 16 were associated with breast cancer patients' RFS and/or OS rates. Well-known lncRNAs like HOTAIR and MALAT1 were identified as central factors associated with patients' survival rates in both networks. Based on the results acquired from our comprehensive in-silico data analysis, we carried out clinical experiments on two less-known lncRNAs, DRAIC and TP53TG1, and found a significant association between them with luminal subtypes of breast cancer. Interestingly, we discovered a significant association between DRAIC and TP53TG1 lncRNAs with ER- and PR-positive samples and lymph-node invasion in breast cancer patients.</p><p><strong>Conclusion: </strong>According to the results, DRAIC and TP53TG1 lncRNAs are overexpressed in breast tumors and may play an oncogenic role with a moderate value of prognosis for luminal subtypes of breast cancer.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1050-1066"},"PeriodicalIF":4.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40628995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of artificial intelligence in breast cancer screening with mammography.","authors":"Lan-Anh Dang,&nbsp;Emmanuel Chazard,&nbsp;Edouard Poncelet,&nbsp;Teodora Serb,&nbsp;Aniela Rusu,&nbsp;Xavier Pauwels,&nbsp;Clémence Parsy,&nbsp;Thibault Poclet,&nbsp;Hugo Cauliez,&nbsp;Constance Engelaere,&nbsp;Guillaume Ramette,&nbsp;Charlotte Brienne,&nbsp;Sofiane Dujardin,&nbsp;Nicolas Laurent","doi":"10.1007/s12282-022-01375-9","DOIUrl":"https://doi.org/10.1007/s12282-022-01375-9","url":null,"abstract":"<p><strong>Objectives: </strong>To demonstrate that radiologists, with the help of artificial intelligence (AI), are able to better classify screening mammograms into the correct breast imaging reporting and data system (BI-RADS) category, and as a secondary objective, to explore the impact of AI on cancer detection and mammogram interpretation time.</p><p><strong>Methods: </strong>A multi-reader, multi-case study with cross-over design, was performed, including 314 mammograms. Twelve radiologists interpreted the examinations in two sessions delayed by a 4 weeks wash-out period with and without AI support. For each breast of each mammogram, they had to mark the most suspicious lesion (if any) and assign it with a forced BI-RADS category and a level of suspicion or \"continuous BI-RADS 100\". Cohen's kappa correlation coefficient evaluating the inter-observer agreement for BI-RADS category per breast, and the area under the receiver operating characteristic curve (AUC), were used as metrics and analyzed.</p><p><strong>Results: </strong>On average, the quadratic kappa coefficient increased significantly when using AI for all readers [κ = 0.549, 95% CI (0.528-0.571) without AI and κ = 0.626, 95% CI (0.607-0.6455) with AI]. AUC was significantly improved when using AI (0.74 vs 0.77, p = 0.004). Reading time was not significantly affected for all readers (106 s without AI and vs 102 s with AI; p = 0.754).</p><p><strong>Conclusions: </strong>When using AI, radiologists were able to better assign mammograms with the correct BI-RADS category without slowing down the interpretation time.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"967-977"},"PeriodicalIF":4.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40407688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}